Hepatic Transporters and Clearance:

Emerging methods to improve drug candidate selection

DATE: Thursday, July 28, 2016 | TIME: 11am ET | DURATION: 1 Hour


Transporters play a critical role in hepatic uptake, metabolism, and clearance.
Drs. Ayman F. El-Kattan and Kim Brouwer will discuss hepatic models that incorporate
transporter function and improve in vitro-in vivo correlation.

Applications of sandwich-cultured hepatocytes in drug discovery
Ayman F. El-Kattan, B. Pharm., Ph.D.
Dr. Ayman F. El-Kattan reviews development of hepatocyte research methods and their application in drug discovery. His discussion includes case studies that illustrate Pfizer's use of sandwich-cultured hepatocytes in research programs.

Dr. El-Kattan is Associate Research Fellow at the Pharmacokinetics, Dynamics, and Metabolism Department, Pfizer Inc. Cambridge Laboratories. His research is focused on understanding the role of transporters in influencing drug disposition and oral absorption. He has investigated the utility of physiological based pharmacokinetic modeling (PBPK) tools in projecting drug disposition and drug-drug interaction liabilities in man for new molecular entities (NME). He is also an Adjunct Professor at the College of Pharmacy-University of Rhode Island and an active member of the American Association of Pharmaceutical Scientists (AAPS) and serves on the executive committee
of the AAPS Drug Transporter focus group.

More about Dr. El-Kattan

Considerations in Selection of a Hepatic Clearance Model
Kim L.R. Brouwer, PharmD, PhD
Dr. Kim Brouwer discusses the importance of basolateral efflux transporters in hepatic drug disposition, and describes the application of B-CLEAR methodology to identify and quantify basolateral vs. biliary clearance in sandwich-cultured hepatocytes.
Dr. Brouwer is Associate Dean for Research and Graduate Education, UNC Eshelman School of Pharmacy, and Kenan Distinguished Professor in the School of Pharmacy and Curriculum in Toxicology at UNC-Chapel Hill. Dr. Brouwer was Founding Director of the UNC Pharmacokinetics/Pharmacodynamics Fellowship Program and she directs an NIH-funded research program focused on hepatobiliary drug disposition, hepatic transport proteins, and development/refinement of in vitro models to predict in vivo hepatic drug disposition, drug interactions, and hepatotoxicity. Dr. Brouwer co-invented B-CLEAR, an in vitro method to assess hepatobiliary disposition, exclusively licensed to Qualyst Transporter Solutions.

More about Dr. Brouwer


Copyright 2011-2012 Qualyst Transporter Solutions, LLC. All Rights Reserved. B-CLEAR is a registered trademark of Qualyst Transporter Solutions, LLC.
*B-CLEAR® is covered by US Patent 6,780,580 and other worldwide patents issued & pending.